Multilink™
New linker for high DAR ADCs
Multilink™ is a new cleavable linker platform compatible with any conjugation technology to produce ADCs with high DAR (drug-to-antibody ratio).
Our value proposition
To allow any biotech or pharma company with an antibody to generate a proprietary clinical-stage ADC (using our Linker Multilink™) that is significantly more effective and better tolerated. Multilink™ is a unique and innovative technology in that it allows the loading of multiple payloads on an antibody
We can generate nonclinical proof-of-concept (POC) material in just a few weeks. Our proprietary linker Multilink™ is suited for ADC technologies, it can be accessed by partners on a target-specific basis. As a first step, we welcome the opportunity to showcase the advantages of our proprietary linker Multilink™ under a joint POC study.
Summary
- New linker system for highly efficient and selective drug release
- Potential increased therapeutic window
- Formation of high DAR ADCs
- Tunable drug release kinetics
- Compatible with all antibody formats and various payloads
- Suitable for payload combinations
- Compatible with various conjugation technologies including site specific technologies
- GMP compatible technology
Press Releases
-
September 21, 2023Read more
Debiopharm and SunRock Biopharma Partner to Advance Antibody Drug Conjugates for Hard-to-Treat Cancers
-
September 22, 2022Read more
Big Impact, Small Package: Debiopharm Launches a Wazoku Open-Innovation Challenge for Small Antibody Drug Conjugate Technology
-
June 16, 2021Read more
Debiopharm and Ubix Therapeutics launch research to develop a new anti-cancer modality – antibody degraducer® conjugates
Publications
-
November 13, 2023Read more
The Multilink(TM) Linker is a promising approach to improve efficacy and safety of ADC’s
-
April 11, 2022Read more
A novel antibody drug conjugate linker enabling production of ADCs with high drug to antibody ratios and fast payload release…
-
April 11, 2022Read more
The antibody-drug conjugate GENA-111 conjugated to auristatin F shows therapeutic potency in BCAM positive epithelial cancer